EUVIMEDEUVIMED entdecken
Open Access

Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability

Wenqiu Zhang, Ju-Hee Oh, Wenjuan Zhang, Courtney C Aldrich, Rachael W Sirianni, William F Elmquist

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.002051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Wenqiu Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pharmaceutics, Brain Barriers Research Center (Wenq. Zhang, J.-H.O., Wenj. Zhang, W.F.E.) and Medicinal Chemistry (C.C.A.), University…. Hauptthemen laut MEDLINE: Indoles, Histone Deacetylase Inhibitors, Hydroxamic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NINDS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The deregulation of histone deacetylase (HDAC) expression is often seen in many cancers, and HDAC inhibitors have shown potency against a variety of cancer types. Panobinostat is a potent pan-HDAC inhibitor that has been tested in multiple studies for the treatment of brain tumors. There have been contrasting views surrounding its efficacy for the treatment of tumors in the central nervous system (CNS) following systemic administration when examined in different models or species. We conducted experiments using three different mouse strains or genotypes to have a more comprehensive understanding of the systemic as well as the CNS distributional kinetics of panobinostat. Our study found that panobinostat experienced rapid degradation in vitro in Friend leukemia virus strain B mouse matrices and a faster degradation rate was observed at 37°C compared with room temperature and 4°C, suggesting that the in vitro instability of panobinostat was due to enzymatic metabolism. Panobinostat also showed interstrain and interspecies differences in the in vitro plasma stability and was stable in human plasma. The objective of this study was to examine the in vitro metabolic stability of panobinostat in different matrices and assess the influence of that metabolic stability on the in vivo pharmacokinetics and CNS delivery of panobinostat. Importantly, the plasma stability in various mouse strains was not reflected in the in vivo systemic pharmacokinetic behavior of panobinostat. Several hypotheses arise from this finding, including: the binding of panobinostat to red blood cells, the existence of competing endogenous compounds to enzyme(s), the distribution into tissues with a lower level of enzymatic activity or the metabolism occurring in the plasma is a small fraction of the total metabolism in vivo. SIGNIFICANCE STATEMENT: Panobinostat showed different in vitro degradation in plasma from different mouse strains and genotypes. However, despite the differences surrounding in vitro plasma stability, panobinostat showed similar in vivo pharmacokinetic behavior in different mouse models. This suggests that the interstrain difference in enzymatic activity did not affect the in vivo pharmacokinetic behavior of panobinostat and its central nervous system distribution in mice. This lack of translation between in vitro metabolism assays and in vivo disposition can confound drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesHistone Deacetylase InhibitorsHydroxamic AcidsAnimalsPanobinostatMiceHumansSpecies SpecificityDrug StabilityMaleMice, Inbred C57BLFemale

Substanzen

PanobinostatIndolesHistone Deacetylase InhibitorsHydroxamic Acids

Autor:innen und Institutionen

  • Departments of Pharmaceutics, Brain Barriers Research Center (Wenq. Zhang, J.-H.O., Wenj. Zhang, W.F.E.) and Medicinal Chemistry (C.C.A.), University of Minnesota, Minneapolis, Minnesota; and Department of Neurologic Su…

Förderung

  • NICHD NIH HHS
  • NINDS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Zhang, W., Oh, J. H., Zhang, W., Aldrich, C. C., Sirianni, R. W., & Elmquist, W. F. (2024). Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.002051

Vancouver

Zhang W, Oh JH, Zhang W, Aldrich CC, Sirianni RW, Elmquist WF. Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.002051

BibTeX
@article{Zhang2024,
  author = {Zhang, Wenqiu and Oh, Ju-Hee and Zhang, Wenjuan and Aldrich, Courtney C and Sirianni, Rachael W and Elmquist, William F},
  title = {Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.002051}
}
Kostenlos starten →